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Supplementation With Multivitamins and Vitamin A
and Incidence of Malaria Among HIV-Infected
Tanzanian Women
Ibironke O. Oloﬁn, MBBS, SD, MPH,* Donna Spiegelman, SD, SM,*†‡§ Said Aboud, MD, PhD,k
Christopher Duggan, MD, MPH,‡¶# Goodarz Danaei, MD, SD,*† and Wafaie W. Fawzi, MBBS, DrPH*†‡
Introduction: HIV and malaria infections occur in the same
individuals, particularly in sub-Saharan Africa. We examined
whether daily multivitamin supplementation (vitamins B complex,
C, and E) or vitamin A supplementation altered malaria incidence in
HIV-infected women of reproductive age.
Methods: HIV-infected pregnant Tanzanian women recruited into
the study were randomly assigned to daily multivitamins (B
complex, C, and E), vitamin A alone, both multivitamins and
vitamin A, or placebo. Women received malaria prophylaxis during
pregnancy and were followed monthly during the prenatal and
postpartum periods. Malaria was deﬁned in 2 ways: presumptive
diagnosis based on a physician’s or nurse’s clinical judgment, which
in many cases led to laboratory investigations, and periodic exami-
nation of blood smears for malaria parasites.
Results: Multivitamin supplementation compared with no multi-
vitamins signiﬁcantly lowered women’s risk of presumptively diag-
nosed clinical malaria (relative risk: 0.78, 95% conﬁdence interval:
0.67 to 0.92), although multivitamins increased their risk of any
malaria parasitemia (relative risk: 1.24, 95% conﬁdence interval:
1.02 to 1.50). Vitamin A supplementation did not change malaria
incidence during the study.
Conclusions: Multivitamin supplements have been previously
shown to reduce HIV disease progression among HIV-infected
women, and consistent with that, these supplements protected
against development of symptomatic malaria. The clinical
signiﬁcance of increased risk of malaria parasitemia among
supplemented women deserves further research, however.
Preventive measures for malaria are warranted as part of an
integrated approach to the care of HIV-infected individuals
exposed to malaria.
Key Words: randomized controlled trial, multivitamin (vitamins B
complex, C, E) supplementation, vitamin A supplementation, HIV-
infected women, malaria incidence
(J Acquir Immune Deﬁc Syndr 2014;67:S173–S178)
INTRODUCTION
Millions of pregnancies occur each year in world
regions affected by malaria transmission.
1 Malaria in preg-
nancy may cause maternal anemia, maternal mortality, pre-
mature pregnancy termination,
2 and low birth weight or death
of the offspring.
3 Furthermore, malaria-endemic regions have
some of the highest burdens of HIV infection globally,
4,5 with
HIV and malaria infections often occurring in the same indi-
viduals. HIV-related immunosuppression increases malaria
susceptibility,
6 whereas malaria may transiently increase
plasma viral load.
7 Both infections may interact detrimentally
in pregnancy to increase risks of pregnancy complications
and adverse infant outcomes.
8–11
Multivitamin supplements, including vitamins B com-
plex, C, and E, slow down disease progression and reduce the
occurrence of HIV-associated complications such as dysentery
and acute upper respiratory infections in HIV-infected
women.
12 Whether multivitamins alter malaria susceptibility
in HIV-infected women is unknown. Studies conducted among
children suggest multivitamins could reduce incidence of clin-
ical malaria,
13 although a possible increase in malaria parasite-
mia was reported by a Gambian randomized trial of thiamine,
riboﬂavin, vitamin C, and iron supplementation.
14 Other stud-
ies suggest that individual vitamins may protect against clinical
malaria, for instance, vitamin A supplementation reduced clin-
ical malaria incidence among children in one study.
15
In this paper, we aim to determine the effect of
multivitamin supplementation on malaria incidence in HIV-
infected women. Multivitamin supplementation in HIV-
infected individuals improves CD4 T-cell counts,
12,16 and the
resulting sustained CD4 T-cell functioning
12,17 could improve
antibody response and protection against malaria.
18,19 In addi-
tion, we examine the effect of vitamin A supplementation on
malaria incidence in HIV-infected women, given protection
previously observed in children. To the best of our knowledge,
randomized trials that addressed these questions are few and
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tions on malaria risk in HIV-infected individuals.
METHODS
A randomized controlled trial was conducted in Dar es
Salaam, Tanzania, from April 1995 until August 2003,
12,20
during which 1078 HIV-infected pregnant women were ran-
domly assigned using a factorial design to receive a daily oral
dose of 1 of 4 regimens: placebo, vitamin A alone (30 mg
b-carotene with 5000 IU preformed vitamin A), multivita-
mins without vitamin A (20 mg vitamins B1,2 0m gB 2,
25 mg B6, 100 mg niacin, 50 mgB 12, 500 mg C, 30 mg E,
and 800 mg folic acid), or multivitamins with vitamin A at the
listed doses. At delivery, women received an additional
200,000 IU oral vitamin A if their assigned regimen included
vitamin A, or placebo if otherwise. Participants and study
staff were blinded to regimen assignments. During the trial
implementation, the Data Safety and Monitoring Board noted
a signiﬁcantly higher risk of mother-to-child transmission of
HIV among women assigned to vitamin A supplementation,
21
whereas multivitamin supplementation reduced the risks of
fetal loss, low birth weight, and severe prematurity.
16,21
Thus, the protocol was modiﬁed to provide multivita-
min supplements for the duration of pregnancy to all
participants who subsequently became pregnant during the
study (starting after May 1998), and to exclude vitamin A
supplements during pregnancy (from September 2000) until
the trial concluded. As we wanted to understand the effects of
multivitamin supplementation, and vitamin A supplementa-
tion, on malaria, we decided a priori to restrict analyses to
contributed person-time that had been unaffected by the
protocol modiﬁcations. These analyses therefore include time
from enrollment to just before the start of a second pregnancy
during the study (314 women had a second pregnancy), or
until the study end, loss to follow-up, or death—whichever
occurred ﬁrst—if no second pregnancy occurred [median (in-
terquartile range) length of follow-up for women with only 1
pregnancy during the study, 41.0 (8.6–75.3) months].
During pregnancy, all women received 120 mg ferrous
iron and 5 mg folate daily and weekly malaria prophylaxis (500
mg chloroquine phosphate) in accordance with standard pre-
natal care in Tanzania at the time. Malaria is endemic in Dar es
Salaam, with year round stable transmission. Iron–folate sup-
plements and prophylactic chloroquine were discontinued when
pregnancy ended. Women diagnosed with malaria were treated
according to the Tanzanian standard of care. Antiretroviral
therapy (ART) was unavailable in Tanzania during the study
period; most study participants were in the early clinical stages
of HIV infection
22 and did not qualify for ART at baseline.
During monthly clinic visits, study nurses evaluated
women for symptoms and history of illnesses, while study
physicians conducted physical examinations, made presumptive
diagnoses, and requested investigations when indicated. Routine
blood smears were universally performed at baseline, the ﬁrst
postnatal visit, and every 12 months, while women suspected to
have malaria at monthly visits had additional blood ﬁlms at their
physicians’ discretion. Thick and thin ﬁlms stained with 5%
Giemsa solution were examined microscopically by 2 labora-
tory technologists for the presence of asexual Plasmodium
falciparum, P. malariae, P. vivax,o rP. ovale parasites. Discor-
dant reports were resolved by a senior laboratory technologist.
We calculated malaria parasite densities per microliter of blood
from the number of parasites per 200 leukocytes, assuming
a leukocyte count of 8000 cells per microliter.
23
Statistical Analysis
Our main outcomes were ﬁrst new episode of any
malaria parasitemia and ﬁrst presumptive diagnosis of clinical
malaria during the study. We also examined intervention
effects on the ﬁrst new episode of $10,000 parasites per
microliter. Presumptive clinical malaria was deﬁned as having
either physician-diagnosed malaria (diagnosis of malaria
made by study physicians after considering symptoms and
clinical examination ﬁndings), nurse-diagnosed malaria (re-
ports of recent high-grade fever with associated chills, rigors,
and sweating and/or axillary temperatures of 37.5°C or higher
recorded by study nurses), or both. Women with any para-
sitemia at enrollment were included in the study after
a 30-day malaria-free period, documented by slides.
We tested differences in baseline characteristics
between intervention groups using t tests or Wilcoxon rank-
sum tests for continuous variables, and x2 tests or Fisher’s
exact tests for categorical variables, as appropriate. Cox pro-
portional hazards regression models,
24 with months since ran-
domization as the time scale, were used to estimate the effects
of treatment on time to ﬁrst malaria episodes. We examined
the effects of multivitamins without vitamin A, vitamin A
alone, and multivitamins with vitamin A, compared with pla-
cebo, on the risk of outcomes and tested for the interaction of
multivitamins with vitamin A using a likelihood ratio test. As
there was no signiﬁcant interaction between multivitamins
and vitamin A supplementation in relation to the risk of ma-
laria, the intervention groups were collapsed to increase sta-
tistical power; multivitamin supplementation was compared
with no multivitamins, and vitamin A was compared with no
vitamin A (interaction test P values were 0.59 in relation to
risk of any parasitemia and 0.24 in relation to risk of pre-
sumptive clinical malaria). We also explored the possibility of
modiﬁcation of the multivitamin effects by the following fac-
tors: gravidity (primigravida or multigravida), season (rainy
or dry season), pregnancy status (pregnant versus no longer
pregnant), time since delivery (#3 versus .3 months), base-
line WHO HIV disease stage
22 (stage 1, 2, or 3), and baseline
CD4 T-cell count (,200, 200 to ,350, $350 cells/mL).
All analyses used SAS software version 9.2 (SAS
Institute, Cary, NC, USA).
25 The Human Subjects Committee
of the Harvard School of Public Health and the Research and
Publications Committee of Muhimbili University of Health and
Allied Sciences gave institutional review board approval for
the randomized trial; women provided informed consent for
participation in the trial.
RESULTS
Of the 1078 trial participants, 1050 were eligible for
this study, contributing a total of 27,551 months of follow-up.
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lost to follow-up immediately after enrollment and 1 had
protracted malaria parasitemia starting at baseline. Five hun-
dred and twenty-eight women received multivitamins and 529
received vitamin A supplements. At baseline (Table 1), most
women were in the second trimester of pregnancy, with 84%
in the ﬁrst WHO clinical stage
22 of HIV infection. Nearly
one-third of the women had CD4 T-cell counts of at least
500 per microliter. Women reported low daily dietary intake
of iron and folate, but moderately high daily vitamin C intake,
compared with the recommended intakes for pregnant
women. More than half had moderate or severe anemia and
plasma vitamin E levels were low, suggesting that many had
multiple micronutrient deﬁciencies. The baseline characteris-
tics of women in the intervention groups were similar. Plas-
modium falciparum caused malaria parasitemia during the
study, and the median time to ﬁrst episode of any parasitemia
after baseline was 18.1 months (interquartile range 6.4–32.3
months), whereas the median time to the ﬁrst presumptive
clinical malaria episode was 9.5 months (interquartile range
2.9–22.8 months).
Supplementation with vitamins B complex, C, and E
appeared protective against presumptive clinical malaria
(Table 2). Women receiving multivitamins compared with
no multivitamins had a lower risk of developing clinical
malaria [22% lower, 95% conﬁdence interval (CI): 8% to
33% lower]—results were similar when physician-diagnosed
and nurse-diagnosed malaria were considered separately. Vita-
min A supplementation compared with no vitamin A did not
signiﬁcantly alter the risk of developing clinical malaria [rela-
tive risk (RR) 0.97, 95% CI: 0.82 to 1.14].
Multivitamin supplementation signiﬁcantly increased
the risk of any malaria parasitemia by 24% (95% CI: 2% to
50%) relative to no multivitamins (Table 3), although at base-
line, the mean parasite counts for the 2 groups were similar
(P = 0.48). When we considered the severity of parasitemia,
malaria parasite densities of $10,000 per microliter were
infrequent—40 women had malaria episodes with $10,000
parasites per microliter. The effect estimate was consistent
with that of any malaria parasitemia, although not statistically
signiﬁcant (severe parasitemia RR 1.23, 95% CI: 0.66 to
2.29). Vitamin A supplementation compared with no vitamin
A did not signiﬁcantly alter the risk of malaria parasitemia
(RR 1.02, 95% CI: 0.84 to 1.24).
Exploration of the modiﬁcation of the effect of
multivitamin supplementation on the risk of malaria
TABLE 1. Baseline Characteristics of Study Participants by Intervention Group*
No Multivitamins (N = 522) Multivitamins (N = 528) No Vitamin A (N = 521) Vitamin A (N = 529)
Age, yrs 25.3 (4.8) 25.4 (4.7) 25.4 (4.8) 25.3 (4.8)
Years of education
None or adult education 7.5 8.7 9.2 7.0
1–4 5.2 5.1 6.1 4.2
5–8 78.5 74.8 75.4 77.9
.8 8.8 11.4 9.2 11.0
Employed outside the home 27.6 26.3 27.3 26.6
Previous pregnancies
0 26.3 26.9 27.1 26.2
1–3 57.3 60.3 58.7 58.8
.3 16.4 12.8 14.2 15.0
Body mass index, kg/m2 23.2 (3.4) 23.4 (3.2) 23.3 (3.3) 23.4 (3.3)
Gestational age at randomization, wk 20.3 (3.6) 20.4 (3.2) 20.5 (3.3) 20.3 (3.4)
CD4 T-cell count, cells/mL
0t o,200 13.3 12.5 13.3 12.5
200 to ,350 25.6 23.8 21.6 27.8
$350 61.0 63.7 65.1 59.7
$500 27.6 29.0 29.2 27.4
WHO HIV disease stage
1 83.1 85.0 85.8 82.4
2 14.6 14.2 13.1 15.7
3 2.3 0.6 1.2 1.7
Plasma viral load† (log) 4.6 (0.8) 4.6 (0.8) 4.6 (0.8) 4.6 (0.8)
Hemoglobin, g/dL 9.5 (1.7) 9.3 (1.6) 9.4 (1.7) 9.4 (1.7)
Plasma vitamin E, mmol/L 9.9 (3.1) 10.1 (3.0) 9.9 (3.1) 10.0 (3.1)
Plasma vitamin A, mmol/L 0.9 (0.4) 0.8 (0.3) 0.9 (0.4) 0.9 (0.3)
Malaria parasitemia‡ 17.1 19.9 16.7 20.2
*Mean 6 SD, median (Q1, Q3), or %. There were no signiﬁcant differences between intervention groups.
†Baseline plasma viral load was measured for 300 randomly selected women, and an additional 115 women involved in a subgroup evaluation.
‡One or more P. falciparum parasites per microliter of blood.
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factors found no modiﬁcation by pregnancy status, time since
delivery, number of previous pregnancies, season, baseline
WHO HIV disease stage, or baseline CD4 T-cell counts (P
values for the interaction test ranged from 0.19 to 0.96 and
0.13 to 0.87, respectively, for malaria parasitemia and pre-
sumptive clinical malaria).
DISCUSSION
We found that daily multivitamin supplementation that
included vitamins B complex, C, and E reduced the risk of
presumptive clinical malaria diagnosis among HIV-infected
women living in a malaria-endemic region. We also found
increased risk of developing any malaria parasitemia for
women receiving multivitamin supplementation. The effects
were similar regardless of pregnancy status, number of
previous pregnancies, season, and WHO HIV disease stage.
Vitamin A supplementation, however, did not change women’s
risks of presumptive clinical malaria or malaria parasitemia.
Our study suggests that multivitamin supplementation
could have prevented clinical malaria episodes, as presump-
tive diagnoses of clinical malaria were less frequent among
HIV-infected women assigned to multivitamins. Multivitamin
supplementation was previously found to result in signiﬁcant
reduction in mortality, increased CD4 T-cell counts, and
reduced plasma viral load among these women.
12 Other stud-
ies have also found vitamin supplementation to be associated
with prolonged AIDS-free survival. The use of vitamin B
supplements by HIV-infected individuals was associated with
delayed progression to AIDS and delayed mortality in South
Africa,
26 and improved survival in the United States.
27 A
randomized controlled trial in Thailand found that multiple
micronutrient supplements (vitamins B complex, A, C, E, D,
K, and minerals) lowered mortality rates among HIV-infected
individuals who were severely immunosuppressed, when
compared with placebo,
28 whereas a trial involving 49 HIV-
infected individuals reported a trend towards reduced viral loads
for those assigned to vitamins C and E compared with pla-
cebo.
29 A recent randomized controlled trial in Botswana also
found that a supplement comprising vitamins B complex, C, E,
and selenium had morbidity-reducing effects among 878 HIV-
infected ART-naive adults.
17 However, although we found mul-
tivitamin supplementation to protect against clinical malaria,
symptoms diagnosed as clinical malaria could also have been
caused by infections other than malaria, in which case, the
protective multivitamin effects we observed would have re-
sulted from a reduced incidence of HIV-related infections,
and not necessarily reductions in clinical malaria incidence.
CD4 T cells play a role in the development of acquired
immunity against malaria,
18,19 and the multivitamin-induced
improvements in immune function could have resulted in
reduced rates of clinical disease. However, it is possible that
other infectious conditions were misidentiﬁed as malaria
among these HIV-infected women—presumptive diagnoses
relied on symptoms and signs that could have non-malaria
causes in HIV-infected individuals.
30 Although our study is
the ﬁrst randomized trial to examine the relationship of vita-
min supplementation with malaria incidence in HIV-infected
women, the offspring of our study participants were investi-
gated for malaria incidence during the ﬁrst 2 years of life.
13
Relative to children of placebo recipients, children whose
mothers received multivitamins alone had signiﬁcantly
reduced clinical malaria rates (71% reduction in malaria inci-
dence) and children whose mothers received both multivitamins
and vitamin A had lower rates of high malaria parasitemia
deﬁned as $5000 parasites per microliter (a 2%–33% reduction
in incidence), although main effects of multivitamins were not
statistically signiﬁcant for both outcomes. These children were
indirectly exposed to maternal supplements, and protection
against malaria observed among children could have been
because women who received multivitamin supplements had
better health outcomes, which may have improved their
capacity to care for their children. For example, children with
healthier mothers may have been more likely to access malaria-
prevention measures like insecticide-treated nets (ITNs), as
access required travel to ITN distribution points.
Multivitamin supplementation increased women’s risks
of malaria parasitemia in this study. Several components of
the multivitamin supplement may have encouraged malaria
parasite growth, especially after women stopped receiving
malaria prophylaxis because their pregnancies ended.
TABLE 2. Effects of Multivitamin Supplementation and
Vitamin A Supplementation on the Risk of Presumptive Clinical
Malaria*
n/person-months IR† RR (95% CI)‡ P
Multivitamins
No multivitamins 312/9588.5 3.25 Ref.
Multivitamins 277/11,214.5 2.47 0.78 (0.67 to 0.92) 0.003
Vitamin A
No vitamin A 292/10,191.2 2.87 Ref.
Vitamin A 297/10,611.8 2.80 0.97 (0.82 to 1.14) 0.70
IR, indicates incidence rate; RR, relative risk.
*First presumptive physician diagnosis of malaria, malaria diagnosed using
symptoms and signs reported to study nurses (self-reported high-grade fever and/or
axillary temperature $37.5°C, with chills, rigors, and associated sweating), or both.
†IR (per 100 person-months).
‡RR (i.e. incidence rate ratio) and 95% CI.
TABLE 3. Effects of Multivitamin Supplementation and
Vitamin A Supplementation on the Risk of Any Malaria
Parasitemia*
n/person-months IR† RR (95% CI)‡ P
Multivitamins
No multivitamins 191/14,507.6 1.32 Ref.
Multivitamins 214/13,043.4 1.64 1.24 (1.02 to 1.50) 0.03
Vitamin A
No vitamin A 199/13,863.9 1.44 Ref.
Vitamin A 206/13,687.1 1.51 1.02 (0.84 to 1.24) 0.84
IR, indicates incidence rate; RR, relative risk.
*First documented post-baseline episode with one or more P. falciparum parasites
per microliter of blood.
†IR (per 100 person-months).
‡RR (i.e. incidence rate ratio) and 95% CI.
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of vitamin C in the human gut
31 could have increased parasite
growth
32—the iron absorption hypothesis is supported by pre-
vious ﬁndings that multivitamins improved hemoglobin con-
centrations of study participants.
33 The antioxidant functions of
vitamins C and E could have reduced parasite susceptibility to
oxidative stressors,
34 and folic acid could have contributed to
DNA synthesis in parasites capable of using exogenous folate.
35
Our ﬁnding of increased malaria parasitemia among recipients
of multivitamin supplementation is consistent with ﬁndings
from another randomized trial, which reported a tendency
toward increased malaria parasite densities among children
who received a supplement containing thiamine, riboﬂavin, vita-
min C, and iron (our multivitamin supplement included these
micronutrients, excepting iron) compared with the placebo,
14
although the elevation in malaria parasitemia seen in that study
may have been because the intervention included iron.
Supplementation with vitamin A did not signiﬁcantly
alter malaria incidence in our study. This is in contrast with
the results of the vitamin A supplementation trial in children
that found supplementation signiﬁcantly reduced P. falcipa-
rum clinical episodes.
15 Earlier vitamin A supplementation
trials found no beneﬁcial effects on P. falciparum density,
probable malaria illness, or malaria-associated mortality.
36
Our study is a randomized controlled trial, in which study
participants and staff were unaware of intervention assignments,
thus could not alter their behavior in favor of any study regimen.
The factorial design enabled us to separately examine multivi-
tamin and vitamin A effects, as well as the interactions between
the two. However, misclassiﬁcation of febrile episodes as
clinical malaria outcomes may have occurred during the study.
Additionally, the infrequency of routine blood ﬁlm samples may
have reduced our ability to detect some episodes of asymptom-
atic parasitemia. The potential for outcome misclassiﬁcation is
complicated by the fact that malaria parasitemia may be
unaccompanied by symptoms in endemic areas
18,37 and that
clinical malaria can be associated with undetectable parasitemia,
for instance when parasites are sequestered in internal organs.
18
This study addresses health problems impacting mil-
lions globally, since malaria and HIV co-infection occur in
many countries, especially in sub-Saharan Africa.
37,38 HIV
infection increases the risk of malaria. It is associated with
reduced malaria immunity
6,39—clinical malaria maybe severe
or fatal in the nonimmune
40,41—and with suboptimal response
to malaria treatment in adults.
42,43 Yet access to malaria-
prevention interventions is still inadequate in many countries.
While 52 countries affected by malaria are on track to reduce
their malaria incidence by 75%, in keeping with World Health
Assembly and Roll Back Malaria targets for 2015, these
countries account for only 4% of global malaria cases.
5
Our ﬁndings are especially generalizable to countries
where ART is provided only to individuals with advanced
HIV infection. Although some countries are adopting lifelong
coverage of ART for all HIV-infected pregnant women
regardless of disease severity (option B+),
44 other countries
continue to recommend lifelong ART only for those with
advanced disease, and provide ART prophylaxis to pregnant
women with less severe disease, to prevent mother-to-child
transmission of HIV during the prenatal and perinatal periods
(option A).
45 As was previously reported, multivitamin
supplementation during pregnancy and in the postpartum
period is beneﬁcial for HIV-infected women, reducing HIV
disease progression
12 and improving the hematologic status of
women and their offspring.
33 Multivitamin supplementation
also improves pregnancy outcomes of HIV-infected women,
reducing the risks of fetal death, low birth weight, and severe
preterm birth,
16 as well as reducing the incidence of clinical
malaria
13 among their offspring. Multivitamin supplements
costing as little as a few cents per person per day could beneﬁt
those who are ineligible for ART, by slowing HIV progres-
sion and reducing complications, possibly including malaria.
Malaria-prevention measures, including vector control meth-
ods and use of ITNs, are recommended by the WHO for all
individuals at risk of malaria.
5
Further research is needed on the effects of multivi-
tamin supplementation in the context of adequate ART.
Also, studies that isolate the effects of individual vitamins
would improve our understanding of causal mechanisms.
Daily use of multivitamin supplements by HIV-infected
women in our study improved clinical outcomes, including
reducing symptomatic malaria infections. The clinical
signiﬁcance of increased malaria parasitemia warrants
additional research, but in light of evidence to date,
multivitamin supplementation is appropriate as part of an
integrated approach to the care of HIV-infected individuals
that includes malaria-prevention measures.
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